Log on / register
BioMed Central home | Journals A-Z | Feedback | Support | My details

This article is part of a series on High risk surgical patient management, edited by David Bennett.

Review

Clinical review: How to optimize management of high-risk surgical patients

Rupert M Pearse1 email, Andrew Rhodes2 and R Michael Grounds3

1Specialist Registrar in Intensive Care, St George's Hospital, London, UK

2Consultant in Anaesthesia and Intensive Care, St George's Hospital, London, UK

3Reader in Anaesthesia and Intensive Care Medicine, St George's Hospital, London, UK

author email corresponding author email

Critical Care 2004, 8:503-507doi:10.1186/cc2922

Published: 6 August 2004

Abstract

For many patients optimal perioperative care may require little or no additional medical management beyond that given by the anaesthetist and surgeon. However, the continued existence of a group of surgical patients at high risk for morbidity and mortality indicates an ongoing need to identify such patients and deliver optimal care throughout the perioperative period. A group of patients exists in whom the risk for death and serious complications after major surgery is in excess of 20%. The risk is related mainly to the patient's preoperative physiological condition and, in particular, the cardiovascular and respiratory reserves. Cardiovascular management of the high-risk surgical patient is of particular importance. Once the medical management of underlying disease has been optimized, two principal areas remain: the use of haemodynamic goals to guide fluid and inotropic therapy, and perioperative β blockade. A number of studies have shown that the use of goal-directed haemodynamic therapy during the perioperative period can result in large reductions in morbidity and mortality. Some patients may also benefit from perioperative β blockade, which in selected patients has also been shown to result in significant mortality reductions. In this review a pragmatic approach to perioperative management is described, giving guidance on the identification of the high-risk patient and on the use of goal-directed haemodynamic therapy and β blockade.


© 1999-2009 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.